ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

9821	Companies
197095	Keywords
128171	Articles
104822	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 07/01/2024 at 07:30, 1 year 7 months ago

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’
OSE Immunotherapeutics publie des résultats précliniques prometteurs sur Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans 'Blood', ouvrant de nouvelles perspectives en immunothérapie pour les patients atteints de LAL

Immunothérapie Publication OSE Immunotherapeutics Lusvertikimab Leucémie Aiguë Lymphoblastique
PRESS RELEASE

published on 07/01/2024 at 07:30, 1 year 7 months ago

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
OSE Immunotherapeutics announces publication of preclinical efficacy results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal 'Blood'. Collaboration with University Medical Center Schleswig-Holstein on targeting ALL patients

OSE Immunotherapeutics Lusvertikimab Acute Lymphoblastic Leukemia Blood Journal IL-7 Receptor Antagonist
BRIEF

published on 06/24/2024 at 07:35, 1 year 7 months ago

OSE Immunotherapeutics signs strategic agreement with MSK for CAR-T cell therapies

OSE Immunotherapeutics Leukemia Memorial Sloan Kettering Cancer Center CAR-T IL-7R
BRIEF

published on 06/24/2024 at 07:35, 1 year 7 months ago

OSE Immunotherapeutics signe un accord stratégique avec MSK pour les thérapies par cellules CAR-T

OSE Immunotherapeutics Leucémie Memorial Sloan Kettering Cancer Center CAR-T IL-7R
PRESS RELEASE

published on 06/24/2024 at 07:30, 1 year 7 months ago

OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T
OSE Immunotherapeutics annonce un accord avec le Memorial Sloan Kettering Cancer Center pour les thérapies CAR-T. L'accord porte sur des brevets dans le traitement des cancers exprimant l'IL-7R

Brevets OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center IL-7R Thérapies CAR-T
PRESS RELEASE

published on 06/24/2024 at 07:30, 1 year 7 months ago

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
OSE Immunotherapeutics partners with Memorial Sloan Kettering Cancer Center for CAR T-cell therapy agreement. MSK to lead development and share revenues with OSE

Agreement CAR T-cell Therapy OSE Immunotherapeutics Memorial Sloan Kettering Cancer Center Revenue Sharing
BRIEF

published on 06/20/2024 at 07:35, 1 year 7 months ago

OSE Immunotherapeutics presents promising data on the mRNA platform at the FOCIS congress

Autoimmune Diseases OSE Immunotherapeutics FOCIS 2024 IL-35 Therapeutic MRNA
BRIEF

published on 06/20/2024 at 07:35, 1 year 7 months ago

OSE Immunotherapeutics présente des données prometteuses sur la plateforme ARNm au congrès FOCIS

Maladies Auto-immunes OSE Immunotherapeutics ARNm Thérapeutique FOCIS 2024 IL-35
PRESS RELEASE

published on 06/20/2024 at 07:30, 1 year 7 months ago

OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)
OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique au congrès annuel FOCIS à San Francisco. L'IL-35 joue un rôle clé dans le contrôle des maladies auto-immunes et inflammatoires

Maladies Auto-immunes OSE Immunotherapeutics ARNm Thérapeutique IL-35 FOCIS
BRIEF

published on 06/05/2024 at 07:35, 1 year 8 months ago

OSE Immunotherapeutics and Nantes University Hospital Present Positive Results in Renal Transplantation

Immunotherapy Clinical Test OSE Immunotherapeutics FR104/VEL-101 Kidney Transplantation

Accesswire

Published on 02/07/2026 at 01:00, 1 day 8 hours ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 10 hours ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 11 hours ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 1 day 18 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 1 day 20 hours ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 21:00, 12 hours 37 minutes ago

Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 17 hours 2 minutes ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 17 hours 17 minutes ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 1 day 14 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 1 day 15 hours ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG

Les Echos

Published on 02/06/2026 at 18:22, 1 day 15 hours ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 1 day 15 hours ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 1 day 17 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 1 day 17 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 2 days 1 hour ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE